Document is current

Article History

Accepted: 22 July 2024

First Online: 14 August 2024

Declarations

:

: This research received no specific grant from any funding agency in the public or commercial or not-for-profit sectors.

: J.R.S. has no competing interests. T.A.C.d.V. reports nonfinancial support from Daiichi Sankyo and personal fees from Bristol-Myers-Squibb, both outside the submitted work. He also reports that he is a member of the adjudication committee of the LIMIT & DANCE trails, which are sponsored by the Population Health Research Institute. M.E.W.H. received consultancy and/or speaker fees from Bayer Netherlands, Daiichi Sankyo, Boehringer Ingelheim, and BMS-Pfizer. Received an unrestricted research grant from the Dutch Federation of Anticoagulation Clinics. R.P. has no competing interests. J.R.d.G. received research grants (through institution) from Atricure Inc, Bayer, Boston, Scientific, Daiichi Sankyo, Johnson&Johnson, Medtronic. Received honoraria/speaker/consultancy fees from AtriaN Medical, Atricure Inc, Bayer, Berlin Chemie, Daiichi Sankyo, Menarini, Medtronic, Novartis, Servier. R.W.M.M. Jansen received honoraria for speaker fees from Bayer Netherlands, Daiichi Sankyo, Boehringer Ingelheim, and BMS-Pfizer.

: J.S., T.d.V., M.H., R.P., J.d.G., and R.J. were involved in drafting and revising the manuscript for intellectual content. All authors gave final approval for this manuscript to be published.

: Data sharing not applicable to this article as no datasets were generated for this review article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.